Drug Type Small molecule drug |
Synonyms HRS 1780, HRS-1780, HRS1780 |
Target |
Action antagonists |
Mechanism MR antagonists(Mineralocorticoid receptor antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Resistant hypertension | Phase 3 | China | - | 23 Jul 2026 |
| Chronic Kidney Diseases | Phase 3 | China | 13 Mar 2026 | |
| Hyperaldosteronism | Phase 2 | China | 20 Apr 2026 | |
| Diabetes Mellitus, Type 2 | Phase 1 | China | 15 Jul 2024 | |
| Heart Failure | IND Approval | China | 21 Nov 2025 |
Phase 2 | 134 | ocibvsqenp(dgqehkvuza) = arzzomyrin lrpiwxsdhu (hdfwtmwsrf ) | Positive | 06 Nov 2025 | |||
ocibvsqenp(dgqehkvuza) = ksnputvvah lrpiwxsdhu (hdfwtmwsrf ) | |||||||
Phase 1 | - | - | HRS-1780 5mg | bjvuyczjkp(lbfsllyjhm) = zwoqekutku qmaoyzuxca (hbzgbxjrwo ) View more | Positive | 26 Aug 2024 | |
HRS-1780 10mg | - |





